Annual Revenue Comparison: United Therapeutics Corporation vs BioMarin Pharmaceutical Inc.

A Decade of Growth: United Therapeutics vs. BioMarin Pharmaceutical

In the competitive landscape of biotechnology, United Therapeutics Corporation and BioMarin Pharmaceutical Inc. have showcased remarkable revenue trajectories over the past decade. From 2014 to 2023, both companies have demonstrated resilience and growth, with United Therapeutics seeing a revenue increase of approximately 81%, while BioMarin's revenue surged by around 222%.

United Therapeutics Corporation

United Therapeutics started 2014 with a revenue of $1.29 billion, steadily climbing to $2.33 billion by 2023. This growth reflects a strategic focus on innovative therapies and expanding market reach.

BioMarin Pharmaceutical Inc.

BioMarin, on the other hand, began with a revenue of $751 million in 2014, reaching $2.42 billion in 2023. This impressive growth underscores BioMarin's commitment to addressing rare genetic diseases, capturing a significant market share.

Both companies exemplify the dynamic nature of the biotech industry, with their revenue trends highlighting strategic advancements and market adaptability.